Analytical Data
-
Gene name
FGG
- Application
-
Alternative Names
FGG;Fibrinogen gamma chain
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P02679
-
Expression Region
27-453aa
-
AA Sequence
YVATRDNCCILDERFGSYCPTTCGIADFLSTYQTKVDKDLQSLEDILHQVENKTSEVKQLIKAIQLTYNPDESSKPNMIDAATLKSRKMLEEIMKYEASILTHDSSIRYLQEIYNSNNQKIVNLKEKVAQLEAQCQEPCKDTVQIHDITGKDCQDIANKGAKQSGLYFIKPLKANQQFLVYCEIDGSGNGWTVFQKRLDGSVDFKKNWIQYKEGFGHLSPTGTTEFWLGNEKIHLISTQSAIPYALRVELEDWNGRTSTADYAMFKVGPEADKYRLTYAYFAGGDAGDAFDGFDFGDDPSDKFFTSHNGMQFSTWDNDNDKFEGNCAEQDGSGWWMNKCHAGHLNGVYYQGGTYSKASTPNGYDNGIIWATWKTRWYSMKKTTMKIIPFNRLTIGEGQQHHLGGAKQVRPEHPAETEYDSLYPEDDL
-
Molecular Weight
55.9 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
FGG (Fibrinogen Gamma) recombinant proteins have garnered significant attention in recent years due to their pivotal role in blood coagulation and potential therapeutic applications. Fibrinogen, a crucial plasma protein, is essential for hemostasis, forming a fibrous mesh that stabilizes blood clots. The gamma chain of fibrinogen, encoded by the FGG gene, is particularly important for modulating interactions with platelets and other coagulation factors. Abnormalities in fibrinogen levels or functions can lead to bleeding disorders or thrombosis. Thus, producing recombinant FGG proteins can provide insights into the molecular mechanisms of coagulation and enable the development of novel therapeutic strategies for managing bleeding conditions and enhancing wound healing. Recent advancements in recombinant DNA technology and protein engineering have facilitated the production of these proteins in various host systems, improving yield and functionality. Studies focused on characterizing the biophysical properties of recombinant FGG, assessing its therapeutic efficacy in preclinical models, and exploring its role in disease contexts have expanded our understanding of fibrinogen’s biological significance. This research is crucial not only for developing targeted treatments for bleeding disorders but also for advancing tissue engineering and regenerative medicine approaches, where controlled modulation of clotting processes is essential. As the field progresses, continued exploration of FGG's therapeutic potential holds promise for innovative solutions in hemophilia treatment, surgical interventions, and personalized medicine strategies.
